Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obervation Letter
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
Resident's Page
2013:79:2;264-267

Pregnancy and varicella infection: A resident's quest

Sangita Ghosh1 , Soumik Chaudhuri2
1 Department of Skin and V.D, PGIMS, Rohtak, India
2 Department of Medicine, PGIMS, Rohtak, India

Correspondence Address:
Sangita Ghosh
42\136, New Ballygunge Road, Kolkata - 39
India
How to cite this article:
Ghosh S, Chaudhuri S. Pregnancy and varicella infection: A resident's quest. Indian J Dermatol Venereol Leprol 2013;79:264-267
Copyright: (C)2013 Indian Journal of Dermatology, Venereology, and Leprology

Introduction

Varicella, or chicken pox, confers lasting immunity and second attacks are uncommon, especially in immunocompetent individuals. Women who reach their child-bearing age without developing immunity to varicella have a small but finite risk of developing chicken pox during pregnancy (0.05-0.07%). [1] Incidence of varicella in pregnancy is calculated to be 2-3/1000 pregnancies. [1] For the mother, the risk of severe illness is greatest after mid pregnancy when she is relatively immunocompromised. For the fetus, the risk of congenital infection is greatest when maternal infection occurs in the first or second trimester.

Maternal Complications Due to Varicella Infection

Although varicella infection is much less common in adults than in children, in persons >15 years of age and children under 1 year of age, it tends to be more severe with a higher rate of complications like pneumonia, hepatitis and encephalitis, and is associated with higher mortality. Pregnant women who contract varicella in the last trimester are at a higher risk of severe pneumonia and death. Pneumonia can occur in up to 10-20% of pregnant women with chicken pox, and the severity of these complications seems to increase in later gestation leading to a mortality rate of 14%, whereas in the general population, varicella pneumonia has a mortality rate of 10-11%. [2],[3],[4] Risk factors for the development of varicella pneumonitis in pregnancy include third trimester infection, cigarette smoking, chronic obstructive lung disease, history of taking systemic steroid in the preceding 3 months or immunosuppression or more than 100 skin lesions or hemorrhagic lesions. [2],[5]

How to Prevent Maternal Varicella?

Pregnant women who have never had varicella infection in the past and/or have not received varicella vaccine, or in whom varicella antibody serology (immunoglobulin gamma) is negative, are considered non-immune. A previous history of chicken pox infection is 97-99% predictive of the presence of serum varicella antibodies. [2]

Varicella zoster immunoglobulin (VZIG), which is a disease-specific immunoglobulin prepared by pooling plasma of donors with high levels of varicella zoster antibody, is recommended as post-exposure prophylaxis for non-immune pregnant women. It has been shown to lower varicella infection rates if administered within 72-96 h after exposure. [1] Protection is estimated to extend through 3 weeks, which corresponds with the half-life of the immunoglobulin. VZIG has no therapeutic benefit once chicken pox has already developed. Aciclovir, as preventive therapy, has been suggested by some authors and is best given on the seventh day post-exposure, but the prophylactic role of this drug in chicken pox is yet to be established. [3]

Varicella vaccine (Varivax) contains live attenuated virus derived from the Oka strain. It is not recommended for pregnant women or for those expected to be pregnant in the next 1 month. However, termination of pregnancy should not be recommended in case of inadvertent vaccination during pregnancy. [6] Varicella vaccination pre-pregnancy (at least 1 month prior conception) or post-partum can be considered for women who are found to be seronegative for VZV IgG before pregnancy or in the post-partum period [Table - 1].

Table 1: CDC guidelines for varicella vaccine and varicella zoster immunoglobulin

How to Manage Maternal Varicella Infection?

Women with significant varicella infection should be treated with oral aciclovir 800 mg five times a day for 7 days starting within 24-72 hours of onset of rash. [3] Aciclovir is a pregnancy category B drug, and, before 20 weeks of gestation, should be used when potential benefits outweigh risk. [7] In case of progression to varicella pneumonitis, if the severity of infection warrants, intravenous aciclovir (10-15 mg/kg, every 8 hours for 5-10 days) can be considered. [4] Fetal ultrasound scan 5 weeks after the primary infection and appropriate follow-up is recommended to all pregnant women who develop varicella during the first or second trimester to screen for fetal abnormalities. They should be advised to avoid contact with other pregnant women and neonates during the period of communicability, which starts 1-2 days prior to the eruption, until the lesions have all crusted, which usually starts 5 days after the onset of rash. Symptomatic treatment and hygiene is advised to prevent secondary bacterial infection of the lesions.

Fetal Complications of Maternal Varicella

Fetal effects of varicella can manifest as either "Fetal or congenital varicella syndrome" (embryopathy) or neonatal varicella (no embryopathy, but chicken pox infection within the first 10-12 days of life). The implications of primary maternal varicella on her baby vary with the gestational age at infection.

Maternal Varicella in the First and Second Trimesters

"Fetal varicella syndrome" develops in <2% of the babies born to mothers infected with varicella between 7 and 28 weeks of pregnancy, through transplacental infection, and it has a mortality rate of 30% in the first month of life. [6] It does not occur at the time of initial fetal infection but results from a subsequent herpes zoster reactivation in utero and only occurs in a minority of the infected fetuses. [3] Clinically, the newborn presents with low birth weight (LBW), cutaneous scars in a dermatomal distribution, papular lesions resembling connective tissue nevi, ocular abnormalities like cataract, microphthalmia and chorioretinitis, bone and muscle hypoplasia, neurological abnormalities like mental retardation, seizures, hydrocephalus, cortical atrophy and microcephaly, Horner′s syndrome, nystagmus and dysfunction of bladder and bowel sphincters. [6]

Maternal Varicella in the Third Trimester

When maternal infection occurs in the last 3 weeks to >5 days before delivery, there is a significant risk (23%) of neonatal varicella despite high titers of passively acquired maternal antibody. [3] The route of infection can be transplacental, ascending vaginal or can result from direct contact with lesions during or after delivery. Transplacentally transmitted infection manifests in the first 10-12 days of life, whereas chicken pox after that time is most likely acquired by post-natal infection. [5]

If the onset of varicella in the mother is 5 days before delivery to 2 days after delivery, an estimated 20-50% of the newborns contract "neonatal varicella," and 30% of them develop "severe or fulminant neonatal varicella" with disseminated cutaneous lesions and visceral involvement [Figure - 1]. This period correlates with the development of maternal IgG; hence, the neonate does not get enough time to acquire passively transferred maternal antibody and there is also a relative immaturity of the neonatal immune system. [8] In that case, the neonate should be given prophylactic VZIG immediately after birth. With the use of VZIG, the mortality rate has declined from 31% to 7% among neonates with severe varicella infection. [9],[10] Aciclovir therapy should be administered promptly within 24 hours of the onset of rash as it reduces the duration and severity of chicken pox at a dosage of 10-15 mg/kg every 8 h intravenously for 5-7 days. [8],[11] Date of delivery may be post-poned allowing maternal antibodies to pass the placental barrier. No controlled study has yet established the effectiveness of aciclovir or valacyclovir for post-exposure prophylaxis to neonates or pregnant women [3] [Table - 2] and [Table - 3].

Figure 1: "Neonatal varicella" in a 6-day-old child whose mother had chicken pox 3 days before delivery
Table 2: Consequences of varicella infection during pregnancy according to gestational age
Table: 3: Management of maternal and neonatal varicella

Conclusion

Chicken pox during pregnancy can have gestational age-specific adverse outcomes both in the mother and in the fetus. Varicella vaccine is contraindicated in pregnancy. Non-immune exposed expectant mothers can be offered VZIG as prophylaxis before infection occurs. Once infection occurs, oral or intravenous aciclovir can be advised depending on the severity of infection. Neonatal varicella infection should be treated promptly with intravenous aciclovir.

References
1.
Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 1994;343:1548-51.
[Google Scholar]
2.
Harger JH, Ernest JM, Thurnau GR, Moawad A, Momirova V, Landon MB, et al. Risk factors and outcome of varicella-zoster virus pneumonia in pregnant women. J Infect Dis 2002;185:422-7.
[Google Scholar]
3.
Tan MP, Koren G. Chickenpox and pregnancy: Revisited. Reprod Toxicol 2005;21:410-20.
[Google Scholar]
4.
Shrim A, Koren G, Yudin MH, Farine D; Maternal Fetal Medicine Committee. Management of varicella infection (chickenpox) in pregnancy. J Obstet Gynaecol Can 2012;34:287-92.
[Google Scholar]
5.
Nathwani D, Maclean A, Conway S, Carrington D. Varicella Infections in pregnancy and the newborn. J Infect 1998;36:59-71.
[Google Scholar]
6.
Pastuszak AL, Levy M, Schick B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med 1994;330:901-5.
[Google Scholar]
7.
Ratanajamit C, Vinther Skriver M, Jepsen P, Chongsuvivatwong V, Olsen J, Sørensen HT. Adverse pregnancy outcome in women exposed to acyclovir during pregnancy: A population-based observational study. Scand J Infect Dis 2003;35:255-9.
[Google Scholar]
8.
Sauerbrei A, Wutzler P. Neonatal varicella. J Perinatol 2001;21:545-9.
[Google Scholar]
9.
Meyers JD. Congenital varicella in term infants: risk reconsidered. J Infect Dis 1974;129:215-7.
[Google Scholar]
10.
Miller E, Cradock-Watson JE, Ridehalgh MK. Outcome in newborn babies given anti-varicella-zoster immunoglobulin after perinatal maternal infection with varicellazoster virus. Lancet 1989;2:371-3.
[Google Scholar]
11.
Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, Feder HM Jr, Feldman S, et al. A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med 1991;325:1539-44.
[Google Scholar]
Show Sections